Patents Assigned to ICURE BNP CO., LTD.
  • Patent number: 11648316
    Abstract: The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 16, 2023
    Assignee: ICURE BNP CO., LTD.
    Inventors: Jin Woo Park, Young Ro Byun, Young Kweon Choi, Kwan Young Chang, Jae Bum Lee
  • Publication number: 20220339261
    Abstract: Proposed is a pharmaceutical composition for oral administration, the composition including an ionic bond complex composed of teriparatide, deoxycholic acid, N?-deoxycholyl-L-lysyl-methylester (DCK), and di-alpha-tocopherol polyethylene glycol 1000 succinate, and a method for preparing the same is also proposed. The oral pharmaceutical composition is useful for the treatment of osteoporosis because the pharmaceutical composition can increase intestinal membrane permeability and oral administration bioavailability of teriparatide and improve patient compliance.
    Type: Application
    Filed: May 13, 2020
    Publication date: October 27, 2022
    Applicant: ICURE BNP CO., LTD.
    Inventors: Young Kweon CHOI, Kwan Young CHANG, Jae Bum LEE, Seohee KANG, Yuseon SEO, Hyerim NA
  • Patent number: 11452705
    Abstract: Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: September 27, 2022
    Assignee: ICURE BNP CO., LTD.
    Inventors: Jin Woo Park, Young Ro Byun, Young Kweon Choi, Kwan Young Chang, Jae Bum Lee
  • Publication number: 20210290586
    Abstract: Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 23, 2021
    Applicant: ICURE BNP CO., LTD.
    Inventors: Jin Woo PARK, Young Ro BYUN, Young Kweon CHOI, Kwan Young CHANG, Jae Bum LEE
  • Patent number: 10918727
    Abstract: Disclosed are a translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide is capable of improving the ability of a target substance to penetrate the cell membrane to thereby effectively deliver the target substance into a living body, including cells, tissue and blood. Thus, the TCTP-PTD peptide may be used for research purposes in vitro, and may be used for clinical purposes, including treatment of various diseases, delivery of contrast agents, etc., and may also be used for diagnostic purposes and in cosmetic applications.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 16, 2021
    Assignee: ICURE BNP CO., LTD.
    Inventors: Kyung Lim Lee, Hea Duk Bae, Jee Hye Maeng